Drug Profile
Research programme: TLR4/MD-2 complex formation inhibitors - BiolineRx/University of Colorado-Boulder
Alternative Names: BL-1110; EDP-34Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator University of Colorado at Boulder
- Developer BioLineRx; University of Colorado at Boulder
- Class Small molecules
- Mechanism of Action Membrane protein inhibitors; Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain; Scleroderma
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Neuropathic-pain(Adjunctive treatment) in Israel (PO)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Neuropathic-pain(Adjunctive treatment) in USA (PO)
- 04 Nov 2017 No recent reports of development identified for research development in Scleroderma in Israel (PO)